Background:

CEA is synthesised during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).

Alternative names:

Carcinoembryonic antigen, CD66e, CEACAM5, Meconium antigen 100

Clonality:

Monoclonal

Species reactivity:

Human, Rat, Mouse

Source:

Mouse

Species:

Human

Cellular localization:

N/A

Isotype:

IgG1

Immunogen:

Synthetic Peptide

Concentration:

1mg/ml

Observed band:

113kDa

Applications:

IHC

Recommended dilution:

IHC 1:200

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.4. Store at -20°C. Avoid repeated freeze-thaw cycles.

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com